1. Home
  2.  » 
  3. Catalent News
  4.  » Catalent to Discuss Data-Driven Development and Patient-Focused Dose Design Strategies at AAPS PharmSci 360

Catalent to Discuss Data-Driven Development and Patient-Focused Dose Design Strategies at AAPS PharmSci 360

SOMERSET, N.J. – October 20, 2020 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that its experts will present at the upcoming American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 event, which takes place virtually from Oct. 26 – Nov. 5, 2020.

On Oct. 26, at 2 p.m. ET, Lisa Caralli, Director of Science and Technology, will present “Data-Driven Strategies to Accelerate Your Molecule’s Development Path”. Ms. Caralli will discuss evidence-based approaches that help avoid development pitfalls and de-risk the path to clinic, including physiologically-based pharmacokinetic (PBPK) modeling, parallel formulation screening, API sparing techniques and optimal early dosing strategies.

Traditional drug development is largely driven by API pharmaceutics, cost and timelines, and can overlook patients’ needs, which may result in a lack of compliance. On Nov. 4, at 9 a.m. ET, Cornell Stamoran, Ph.D., Vice President of Corporate Strategy and founder of the Catalent Applied Drug Delivery Institute (“Catalent Institute” – www.drugdeliveryinstitute.com), and William Chin, Ph.D., Manager, Global Scientific Affairs, will discuss dose design strategies that can be employed to better serve patients in their presentation, “Patient-Focused Drug Design: A Structured Approach to Dose Form Design to Develop Better Treatments that Address Patient Needs”.

Ms. Caralli has over 27 years of industry experience, and in her role at Catalent works with pharmaceutical companies to identify appropriate development pathways for early development drug candidates. She has previously held roles at Ionis Pharmaceuticals and Amylin Pharmaceuticals, having begun her career at the Immune Response Corporation. Ms. Caralli holds a bachelor’s degree in biochemistry from the University of California, Davis, California.

Dr. Stamoran leads Catalent’s strategic planning, market intelligence and government affairs efforts. He also founded and serves as Co-Chair of the Catalent Institute. He has spent more than 30 years engaged in the healthcare industry, including over 25 years in advanced drug and biologic delivery and outsourcing.

Dr. Chin has experience in in vitro and in vivo evaluation of pharmaceutical formulations and drug delivery systems, specializing in oral solid dosage formulation, Phase 1 and 2 process development for pediatrics, and first-in-human trials. Dr. Chin received his doctoral degree from the Department of Pharmacy at the National University of Singapore.

For more information, please visit https://www.catalent.com/events/aaps-2020/.

ABOUT CATALENT

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

 

More products. Better treatments. Reliably supplied.™